Fresenius Medical Care, the world’s largest provider of dialysis products and services, today has signed a merger agreement to acquire NxStage Medical, Inc. (NASDAQ: NXTM), a U.S.-based medical technology and services company.
Pursuant to the merger agreement, Fresenius Medical Care North America has agreed to acquire all outstanding shares of NxStage Medical, Inc. for USD 30.00 per common share in cash.
The planned acquisition has a total transaction volume of approximately EUR1 1.7 billion (USD 2.0 billion). Closing is currently expected to occur in 2018.
Completion of the merger is subject to approval of NxStage Medical, Inc. stockholders, receipt of regulatory approvals and other customary closing conditions.
1 Based on an exchange rate of 0.849 USD/EUR as per 5 August 2017.
Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,690 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 315,305 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
Disclaimer Regarding Forward-Looking Statements
This release contains forward-looking statements, including statements regarding Fresenius Medical Care’s planned acquisition of NxStage Medical, Inc. and the expected timing of the closing of the transaction. Actual results could differ materially from those expressed or implied in these forward-looking statements due to certain factors, including, among others: the failure or inability of either Fresenius Medical Care or NxStage Medical, Inc. to satisfy closing conditions or obtain approvals necessary to close the transaction; unexpected costs or delays associated with efforts to obtain the regulatory or other approvals necessary to close the transaction; risks associated with litigation or regulatory actions related to the transaction; changes in business, economic and competitive conditions; regulatory reforms; foreign exchange rate fluctuations; risks and uncertainties in litigation or investigative proceedings, whether or not related to the transaction; and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.